AAPS PharmSciTech

, Volume 14, Issue 4, pp 1333–1340 | Cite as

Stability of Benzocaine Formulated in Commercial Oral Disintegrating Tablet Platforms

  • Melanie Köllmer
  • Carmen Popescu
  • Prashanth Manda
  • Leon Zhou
  • Richard A. Gemeinhart
Research Article

Abstract

Pharmaceutical excipients contain reactive groups and impurities due to manufacturing processes that can cause decomposition of active drug compounds. The aim of this investigation was to determine if commercially available oral disintegrating tablet (ODT) platforms induce active pharmaceutical ingredient (API) degradation. Benzocaine was selected as the model API due to known degradation through ester and primary amino groups. Benzocaine was either compressed at a constant pressure, 20 kN, or at pressure necessary to produce a set hardness, i.e., where a series of tablets were produced at different compression forces until an average hardness of approximately 100 N was achieved. Tablets were then stored for 6 months under International Conference on Harmonization recommended conditions, 25°C and 60% relative humidity (RH), or under accelerated conditions, 40°C and 75% RH. Benzocaine degradation was monitored by liquid chromatography–mass spectrometry. Regardless of the ODT platform, no degradation of benzocaine was observed in tablets that were kept for 6 months at 25°C and 60% RH. After storage for 30 days under accelerated conditions, benzocaine degradation was observed in a single platform. Qualitative differences in ODT platform behavior were observed in physical appearance of the tablets after storage under different temperature and humidity conditions.

Key words

benzocaine degradation oral disintegrating tablet platform stability 

Notes

ACKNOWLEDGMENTS

This investigation was conducted in a facility constructed with support from Research Facilities Improvement Program Grant C06 RR15482 from the National Centre for Research Resources, NIH. This research was funded in part by Roquette America, Inc. The authors would like to thank Dr. Jerry White and Bryan Zahakaylo of UIC-RRC Mass Spectrometry Facility for significant help with LC-MS.

REFERENCES

  1. 1.
    Fu YR, Yang SC, Jeong SH, Kimura S, Park K. Orally fast disintegrating tablets: developments, technologies, taste-masking and clinical studies. Crit Rev Ther Drug. 2004;21(6):433–75.CrossRefGoogle Scholar
  2. 2.
    Douroumis D. Orally disintegrating dosage forms and taste-masking technologies; 2010. Expert Opin Drug Deliv. 2011;8(5):665–75.PubMedCrossRefGoogle Scholar
  3. 3.
    Montgomery W, Treuer T, Karagianis J, Ascher-Svanum H, Harrison G. Orally disintegrating olanzapine review: effectiveness, patient preference, adherence, and other properties. Patient Prefer Adherence. 2012;6:109–25.PubMedCrossRefGoogle Scholar
  4. 4.
    Navarro V. Improving medication compliance in patients with depression: use of orodispersible tablets. Adv Ther. 2010;27(11):785–95.PubMedCrossRefGoogle Scholar
  5. 5.
    US FDA. Guidance for industry orally disintegrating tablets. Silver Spring, MD: Office of Pharmaceutical Science in the Center for Drug Evaluation and Research (CDER) at the Food and Drug Administration; 2008.Google Scholar
  6. 6.
    Wu Y, Levons J, Narang AS, Raghavan K, Rao VM. Reactive impurities in excipients: profiling, identification and mitigation of drug–excipient incompatibility. AAPS PharmSciTech. 2011;12(4):1248–63.PubMedCrossRefGoogle Scholar
  7. 7.
    Prasad A, Langley N. The effect of secondary oxidation impurities in PVP on API stability. Tarrytown, NY: BASF CorporationGoogle Scholar
  8. 8.
    ICH. Stability testing of new drug substances and products Q1A(R2). Step 4: International Conference on the Harmonisation of Technical Requirements for Registration of Pharmaceutical for Human Use; 2003.Google Scholar
  9. 9.
    Branch SK. Guidelines from the International Conference on Harmonisation (ICH). J Pharm Biomed Anal. 2005;38(5):798–805.PubMedCrossRefGoogle Scholar
  10. 10.
    Rumbelow S, Brown JC, editors. Investigations into drug stability using LC-MS-MS data and statistical data processing. 57th American Society of Mass Spectrometry, Philadelphia, USA; 2009.Google Scholar
  11. 11.
    Narang PK, Bird G, Crouthamel WG. High-performance liquid chromatographic assay for benzocaine and p-aminobenzoic acid including preliminary stability data. J Pharm Sci. 1980;69(12):1384–7.PubMedCrossRefGoogle Scholar
  12. 12.
    del Barrio MA, Hu J, Zhou P, Cauchon N. Simultaneous determination of formic acid and formaldehyde in pharmaceutical excipients using headspace GC/MS. J Pharm Biomed Anal. 2006;41(3):738–43.PubMedCrossRefGoogle Scholar
  13. 13.
    Waterman KC, Arikpo WB, Fergione MB, Graul TW, Johnson BA, Macdonald BC, et al. N-Methylation and N-formylation of a secondary amine drug (varenicline) in an osmotic tablet. J Pharm Sci. 2008;97(4):1499–507.PubMedCrossRefGoogle Scholar
  14. 14.
    Crowley PJ, Martini LG. Effects of excipients on the stability of medicinal products. Chem Today. 2010;28(5 Supplement):VII–XIII.Google Scholar
  15. 15.
    El-Banna HM, Daabis NA, El-Fattah SA. Aspirin stability in solid dispersion binary systems. J Pharm Sci. 1978;67(11):1631–3.PubMedCrossRefGoogle Scholar
  16. 16.
    Wirth DD, Baertschi SW, Johnson RA, Maple SR, Miller MS, Hallenbeck DK, et al. Maillard reaction of lactose and fluoxetine hydrochloride, a secondary amine. J Pharm Sci. 1998;87(1):31–9.PubMedCrossRefGoogle Scholar
  17. 17.
    George RC, Barbuch RJ, Huber EW, Regg BT. Investigation into the yellowing on aging of Sabril® tablet cores. Drug Dev Ind Pharm. 1994;20:3023–32.CrossRefGoogle Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2013

Authors and Affiliations

  • Melanie Köllmer
    • 1
  • Carmen Popescu
    • 2
  • Prashanth Manda
    • 2
    • 3
  • Leon Zhou
    • 2
  • Richard A. Gemeinhart
    • 1
    • 4
    • 5
  1. 1.Department of Biopharmaceutical SciencesUniversity of IllinoisChicagoUSA
  2. 2.Roquette America Inc.GenevaUSA
  3. 3.Department of PharmaceuticsUniversity of MississippiUniversityUSA
  4. 4.Department of BioengineeringUniversity of IllinoisChicagoUSA
  5. 5.Department of Ophthalmology and Visual SciencesUniversity of IllinoisChicagoUSA

Personalised recommendations